Endocrinology, Vol 120, 1658-1662, Copyright © 1987 by Endocrine Society

ARTICLES

The growth hormone (GH)-releasing hormone (GHRH)-GH-somatomedin axis: evidence for rapid inhibition of GHRH-elicited GH release by insulin- like growth factors I and II

GP Ceda, RG Davis, RG Rosenfeld and AR Hoffman

Hypothalamic-pituitary-end-organ axes are frequently controlled by long loop negative feedback homeostatic mechanisms. Insulin-like growth factor I (IGF-I), IGF-II, and insulin receptors have recently been described in normal and neoplastic rat and acromegalic human pituitary cells, a finding which suggests the possibility that somatomedins might exert feedback at the level of the anterior pituitary. To study the kinetics of this feedback response, we used perifused dispersed rat anterior pituitary cells to learn if somatomedins or insulin could inhibit GH-releasing hormone (GHRH)-stimulated GH secretion. Cells were exposed to hourly boluses of 1 nM GHRH with or without varying doses of IGF or insulin. IGF-I inhibited GHRH-elicited GH release with an IC50 of 6.5 nM; maximal inhibition (approximately 67%) was achieved with 10 nM IGF-I. IGF-II was a less potent hormone, with 10 nM inhibiting about 30% of GHRH-stimulated GH release. Slight inhibition of stimulated GH release (less than 15%) was seen when cells were treated with insulin, but only when doses of insulin of 10 nM or more were used. In conclusion, nanomolar concentrations of IGF-I and IGF-II inhibited GHRH- elicited GH release from perifused rat pituitary cells in a dose- dependent manner; and insulin was not an effective inhibitor of stimulated GH release at physiological peptide concentrations. In conjunction with our previous findings that the concentrations of IGF-I and IGF-II receptors greatly exceed that of insulin receptors on normal rat pituitary cells, we hypothesize that the GH-inhibiting action of high dose insulin is mediated through an IGF receptor.

This article has been cited by other articles:

				J. D. Veldhuis, J. N. Roemmich, E. J. Richmond, and C. Y. Bowers Somatotropic and Gonadotropic Axes Linkages in Infancy, Childhood, and the Puberty-Adult Transition Endocr. Rev., April 1, 2006; 27(2): 101 - 140. [Abstract] [Full Text] [PDF]

				D. L. Hadsell, D. T. Torres, N. A. Lawrence, J. George, A. F. Parlow, A. V. Lee, and M. L. Fiorotto Overexpression of Des(1-3) Insulin-Like Growth Factor 1 in the Mammary Glands of Transgenic Mice Delays the Loss of Milk Production with Prolonged Lactation Biol Reprod, December 1, 2005; 73(6): 1116 - 1125. [Abstract] [Full Text] [PDF]

				H. Zhou, X. Wang, W. K. W. Ko, and A. O. L. Wong Evidence for a Novel Intrapituitary Autocrine/Paracrine Feedback Loop Regulating Growth Hormone Synthesis and Secretion in Grass Carp Pituitary Cells by Functional Interactions between Gonadotrophs and Somatotrophs Endocrinology, December 1, 2004; 145(12): 5548 - 5559. [Abstract] [Full Text] [PDF]

				C. A. Jaffe, W. Pan, M. B. Brown, R. DeMott-Friberg, and A. L. Barkan Regulation of GH Secretion in Acromegaly: Reproducibility of Daily GH Profiles and Attenuated Negative Feedback by IGF-I J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4364 - 4370. [Abstract] [Full Text] [PDF]

				J. D. Wallace, R. C. Cuneo, M. Bidlingmaier, P. A. Lundberg, L. Carlsson, C. L. Boguszewski, J. Hay, M. Boroujerdi, A. Cittadini, R. Dall, et al. Changes in Non-22-Kilodalton (kDa) Isoforms of Growth Hormone (GH) after Administration of 22-kDa Recombinant Human GH in Trained Adult Males J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1731 - 1737. [Abstract] [Full Text]

				M. Maccario, F. Tassone, L. Gianotti, F. Lanfranco, S. Grottoli, E. Arvat, E. E. Muller, and E. Ghigo Effects of Recombinant Human Insulin-Like Growth Factor I Administration on the Growth Hormone (GH) Response to GH-Releasing Hormone in Obesity J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 167 - 171. [Abstract] [Full Text]

				L. Gianotti, M. Maccario, F. Lanfranco, J. Ramunni, L. Di Vito, S. Grottoli, E. E. Muller, E. Ghigo, and E. Arvat Arginine Counteracts the Inhibitory Effect of Recombinant Human Insulin-Like Growth Factor I on the Somatotroph Responsiveness to Growth Hormone-Releasing Hormone in Humans J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3604 - 3608. [Abstract] [Full Text]

				L. Gianotti, A. I. Pincelli, M. Scacchi, M. Rolla, D. Bellitti, E. Arvat, F. Lanfranco, A. Torsello, E. Ghigo, F. Cavagnini, et al. Effects of Recombinant Human Insulin-Like Growth Factor I Administration on Spontaneous and Growth Hormone (GH)-Releasing Hormone-Stimulated GH Secretion in Anorexia Nervosa J. Clin. Endocrinol. Metab., August 1, 2000; 85(8): 2805 - 2809. [Abstract] [Full Text]

				Y. J. H. Janssen, F. Helmerhorst, M. Frölich, and F. Roelfsema A Switch from Oral (2 mg/Day) to Transdermal (50 {micro}g/Day) 17{beta}-Estradiol Therapy Increases Serum Insulin-Like Growth Factor-I Levels in Recombinant Human Growth Hormone (GH)-Substituted Women with GH Deficiency J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 464 - 467. [Abstract] [Full Text]

				E. Ghigo, L. Gianotti, E. Arvat, J. Ramunni, M. R. Valetto, F. Broglio, M. Rolla, F. Cavagnini, and E. E. Müller Effects of Recombinant Human Insulin-Like Growth Factor I Administration on Growth Hormone (GH) Secretion, Both Spontaneous and Stimulated by GH-Releasing Hormone or Hexarelin, a Peptidyl GH Secretagogue, in Humans J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 285 - 290. [Abstract] [Full Text]

				A. Rahim, P. A. O’Neill, and S. M. Shalet Growth Hormone Status during Long-Term Hexarelin Therapy J. Clin. Endocrinol. Metab., May 1, 1998; 83(5): 1644 - 1649. [Abstract] [Full Text]

				D. Ray and S. Melmed Pituitary Cytokine and Growth Factor Expression and Action Endocr. Rev., April 1, 1997; 18(2): 206 - 228. [Abstract] [Full Text]